Biocartis Group NV: Disclosure of outstanding voting securities
(Thomson Reuters ONE) -
PRESS RELEASE: REGULATED INFORMATION
10 October 2017, 07:00 CEST
Disclosure of Outstanding Voting Securities
Mechelen, Belgium, 10 October 2017 - Biocartis Group NV (the 'Company' or
'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels:
BCART), today announces that 21,667 new shares were issued as a result of the
exercise of stock options (each stock option having the form of a warrant) under
the 2013 Plan for employees, consultants and management members.
In view hereof, and in accordance with article 15 of the Belgian Act of 2 May
2007 on the disclosure of major shareholdings in issuers of which shares are
admitted to trading on a regulated market and laying down miscellaneous
provisions (the 'Belgian Act'), the outstanding share capital and outstanding
voting securities of the Company can be summarised as follows:
* Total outstanding share capital: EUR 446,697.72;
* Total outstanding voting securities: 44,669,772 shares;
* Total outstanding voting rights: 44,669,772 voting rights;
* Shares that can still be issued: 7,122,089 shares (each share entailing one
voting right), of which:
* 810,804 shares can be issued upon the exercise of 810,804 outstanding
stock options (each stock option having the form of a warrant) that are
still outstanding under the 2013 Plan for employees, consultants and
management members, entitling the holders thereof to acquire one new
share per option;
* 262,934 shares can be issued upon the exercise of 262,934 outstanding
stock options (each stock option having the form of a warrant) that are
still outstanding under the 2015 Plan for employees, consultants,
management members and directors, entitling the holders thereof to
acquire one new share per option;
* 1,340,000 shares can be issued upon the exercise of 1,340,000
outstanding stock options (each stock option having the form of a
warrant) that are still outstanding under the 2017 Plan for the CEO,
entitling the holder thereof to acquire one new share per option;
* 4,708,351 shares can be issued pursuant to a conversion option agreement
entered into between Koninklijke Philips N.V. ('Philips') and the
Company[1].
Pursuant to the Belgian Act and the articles of association of the Company, a
notification to the Company and the Belgian Financial Services and Markets
Authority (FSMA) is required by all natural and legal persons in each case where
the percentage of voting rights attached to the securities held by such persons
in the Company reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and
every subsequent multiple of 5%, of the total number of voting rights in the
Company.
----- END ----
More information:
Renate Degrave
Manager Corporate Communications & Investor Relations Biocartis
email rdegrave(at)biocartis.com
tel +32 15 631 729 | mobile +32 471 53 60 64
About Biocartis
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics
(MDx) company providing next generation diagnostic solutions aimed at improving
clinical practice for the benefit of patients, clinicians, payers and industry.
Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-
result, real-time PCR (Polymerase Chain Reaction) system that offers accurate,
highly reliable molecular information from virtually any biological sample in
virtually any setting. Biocartis launched the Idylla(TM) platform in September
2014. Biocartis is developing and marketing a rapidly expanding test menu
addressing key unmet clinical needs in oncology and infectious diseases. These
areas represent respectively the fastest growing and largest segments of the MDx
market worldwide. Today, Biocartis offers ten oncology tests and two infectious
disease tests in Europe. More information: www.biocartis.com. Press Photo
Library available here. Follow us on Twitter: (at)Biocartis_.
The Biocartis trademark and logo are trademarks of Biocartis and are used and
registered in Europe. Idylla(TM) is a registered trademark in the United States
and other countries. The Idylla(TM) trademark and logo are trademarks of and
used by Biocartis. This press release is not for distribution, directly or
indirectly, in any jurisdiction where to do so would be unlawful. Any persons
reading this press release should inform themselves of and observe any such
restrictions. Biocartis takes no responsibility for any violation of any such
restrictions by any person. Please refer to the product labeling for applicable
intended uses for each individual Biocartis product. This press release does not
constitute an offer or invitation for the sale or purchase of securities in any
jurisdiction. No securities of Biocartis may be offered or sold in the United
States of America absent registration with the United States Securities and
Exchange Commission or an exemption from registration under the U.S. Securities
Act of 1933, as amended.
Forward-looking statements
This press release may contain forward-looking statements. Such forward-looking
statements are not guarantees of future performance. These forward-looking
statements speak only as of the date of this press release. Biocartis expressly
disclaims any obligation or undertaking to release any updates or revisions to
any forward-looking statements in this press release. You should not place undue
reliance on forward-looking statements.
--------------------------------------------------------------------------------
[1] The conversion option agreement allows Philips to convert certain royalty
and other payments due to it up to a maximum of 10% of the then outstanding
capital of the Company on a fully diluted post-money basis, but only if the
Company has not yet made a lump sum payment in lieu of such royalty and other
payments, and the conversion can only be exercised by Philips upon the
acceptance of the exercise by the Company at its sole discretion. The number of
4,708,351 shares that can still be issued assumes that all outstanding warrants
(entailing the issue of up to 2,413,738 new shares) have been exercised, it
being understood that the actual number of shares issuable depends on a number
of factors.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biocartis Group NV via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="QYOU strikes again in Portugal with NOWODatum: 10.10.2017 - 07:00 Uhr
Sprache: Deutsch
News-ID 562958
Anzahl Zeichen: 7550
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 249 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biocartis Group NV: Disclosure of outstanding voting securities"
steht unter der journalistisch-redaktionellen Verantwortung von
Biocartis Group NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
